IRD
Opus Genetics, Inc.
NASDAQ · USHealthcareBiotechnology
$3.05-6.73%
Price as of Jul 20, 2026
IRD financials
Opus Genetics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $14.2M | $11.0M | $19.0M | $39.9M |
| Operating expenses | $52.8M | $73.1M | $29.6M | $21.6M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M |
| EBITDA | -$48.1M | -$57.5M | -$10.0M | $18.2M |
| Basic EPS | $-0.80 | $-2.15 | $-0.46 | $0.90 |
| Diluted EPS | $-0.80 | $-2.15 | $-0.46 | $0.87 |
| Balance sheet | ||||
| Cash & equivalents | $45.1M | $30.3M | $50.5M | $42.6M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M |
| Total liabilities | $34.9M | $30.1M | $4.0M | $2.8M |
| Stockholders’ equity | $15.3M | $6.7M | $49.9M | $46.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Net debt | -$45.1M | -$30.3M | -$50.5M | -$42.6M |
| Cash flow | ||||
| Operating cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | -$35.3M | -$25.6M | -$1.1M | $14.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$152.0K | -$79.0K | $0.00 | $0.00 |